Marijuana
Diabetic Peripheral Neuropathic Pain
Syqe MedicalPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 81/ 100
Competitive context
18 Active assets in the Diabetic Peripheral Neuropathic Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ds-5565 Bangladesh Medical University | Phase 4 | BBB |
Pregabalin Shandong Suncadia Medicine Co., Ltd. | Phase 4 | BBB |
Ranolazine Horizons International Peripheral Group | Phase 4 | B |
Pilavapadin Lexicon Pharmaceuticals | Phase 2 | B |
Nyx-2925 Aptinyx | Phase 2 | B |
View all 27 →
Same molecule, other indications
Marijuana is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →